CClinicalTrials.gg
CompletedNCT03296592CSMUpdated Mar 17, 2026

Diffusion MRI in Cervical Spondylotic Myelopathy (CSM)

An observational study in Cervical Spondylotic Myelopathy, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Washington University School of Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
71
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patients who have been diagnosed with Cervical Spondylotic Myelopathy will be asked to undergo an MRI using diffusion basis spectrum imaging (DBSI) technology. The patients will have this MRI preoperatively and at 24 months postop. The investigators believe that with this imaging, biomarkers will be able to be seen to assist in prediction of long term outcomes in patients with spinal cord compression. These patients will be compared to healthy cohorts who will also undergo an MRI using the DBSI technology.

Read the detailed description

CSM is the most common form of spinal cord injury and is the leading cause of progressive disability in patients over the age of 65. A major shortcoming limiting the clinical management of CSM is the lack of quantifiable metrics to 1) base clinical decisions and 2) predict potential for functional recovery following surgical intervention. DBSI MRI will provide imaging biomarkers to more reliably predict a patient's clinical course, response to therapy, and long-term prognosis.

Patients who are diagnosed with CSM will have an MRI using the DBSI technology preoperatively and at 24 months. Surgical patients will be assessed with the Neck Disability Index (NDI), Disability of the Arm, Shoulder and Hand (DASH), hand grip dynamometer and Manual Muscle Testing (MMT), the modified Japanese Orthopaedic Association scale (mJOA), and the Major Depression Inventory (MDI), the Short Form-36 (SF-36) and Nurick scoring.

A control group of healthy volunteers will have an MRI using the DBSI technology when enrolled and then again between 12-24 months later.

02

Conditions studied

  • Cervical Spondylotic Myelopathy

Keywords

  • myelopathy
  • diffusion MRI
  • spinal cord injury
  • spinal cord compression
  • spondylosis
  • cervical
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We will enroll from our patient population and 20 patients from healthy volunteers.

Inclusion criteria

  • History of ongoing spinal cord compression,
  • clinical evidence of CSM as determined by signs and symptoms including, but not limited to loss of manual dexterity, extremity weakness, sensory abnormalities, quadriparesis, loss of proprioception, and positive Babinski's or Hoffman's sign.

Exclusion criteria

Exclusion Criteria:

  • pregnant
  • having an MRI incompatible device
  • having a known diagnosis of amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, concomitant thoracic and/or lumbar stenosis, spine tumor or HIV-related myelopathy and having systemic instability or being deemed unable to tolerate standard MRI sequencing.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
71 participants (actual)
Patient registry
No

Groups and cohorts

  • Investigational subjects

    Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis. Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment. Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment. Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI.

    Diagnostic Test: MRI with DBSI technology

  • Control group

    Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI

    Diagnostic Test: MRI with DBSI technology

Interventions

  • Diagnostic testMRI with DBSI technology

    The MRI will be done with diffusion basis spectrum imaging

05

What researchers measure

Primary outcomes

  1. Accurate prediction of neurologic outcomes after surgery

    Outcome measure will assess spinal cord DBSI pathological metrics at baseline and at 24 months.

    Time frame: 24 months

Secondary outcomes

  1. Assessment of effects of blood flow deficits on spinal cord pathology

    Outcome measure will assess effects of blood flow deficits on spinal cord pathology and determine the accuracy of axonal loss quantification in CSM

    Time frame: 24 months

06

Study locations

1 site
  • Washington University
    St Louis, Missouri 63110, United States
07

References and documents

Individual participant data

Plan to share: No — The investigators will not share individual participant data with other researchers. Aggregate data will be made available at study completion.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03296592
Lead sponsor
Washington University School of Medicine
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
Responsible party
Wilson Z. Ray (Principal Investigator, Washington University School of Medicine) — Principal investigator
First posted
Sep 28, 2017
Start date
Jan 29, 2018
Primary completion
Mar 30, 2024
Completion
Dec 29, 2025
Last update
Mar 17, 2026

Study contacts

Wilson Z Ray, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion